Medindia

X

Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011

Wednesday, June 1, 2011 General News J E 4
Advertisement

ANAHEIM, Calif., June 1, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at The Jefferies Global Healthcare Conference to be held June 6-9, 2011 at the Grand Hyatt in New York City.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Thursday, June 9, 2011 at 10:30 a.m. ET.

To listen to the audio web cast of the presentation during or after the event, please visit: www.questcor.com.  The replay will be available for ninety days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
STAAR Surgical Receives Two Key Regulatory Approva...
S
Grifols and Talecris Biotherapeutics Announce the ...